Tianjin Ringpu Bio Tech (300119) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Tianjin Ringpu Bio Tech ¥15.08, price ¥16.66, upside -9.5%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Tianjin Ringpu Bio Tech for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥10.91 – ¥38.60 · fair‑value band ¥8.46 – ¥19.12 · the ¥16.66 price screens above the ¥15.08 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Tianjin Ringpu Bio Tech in your weekly email
Every Wednesday you see whether Tianjin Ringpu Bio Tech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, pharmaceutical preparation, functional additives, and veterinary biological products.
Show more
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, pharmaceutical preparation, functional additives, and veterinary biological products. The company provides vaccines, chemical drugs, traditional Chinese medicines; feed additives, including pigs, chickens, waterfowl, cattle, sheep and pet medicines, and vaccines; and poultry, waterfowl, livestock, rumination, pets, washing and disinfection, active pharmaceutical ingredients product series. It also offers diagnosis and treatment services, such as epidemic diagnosis and testing, animal drug evaluation, and veterinary socialization. The company was founded in 1998 and is headquartered in Tianjin, China.
Stock analysis
Tianjin Ringpu Bio Tech (300119) currently trades at ¥16.66, while our model-based Fair Value estimate is ¥15.08, implying the stock looks roughly 10.5% fairly valued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥20.16 per share, and 9 of the 26 models we run sit above the ¥16.66 price.
Bear case: the Dividend Discount group reads lowest at ¥4.61, and 17 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: ¥8.46 (bear) to ¥19.12 (bull), the price of ¥16.66 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Tianjin Ringpu Bio Tech reported revenue of 3.4B CNY in FY2025 versus 2.0B CNY in FY2021, a compound +14.1%/yr. Reported net income was 401M CNY in FY2025, compounding −0.8%/yr from FY2021.
Key figures
Market cap 7.7B CNY (≈ $1.2B) · P/E ratio 19.4 · P/S ratio 2.28 · EPS (TTM) ¥0.8600 · Dividend yield 2.4% · Net margin 11.8% · Return on equity 8.3% · Return on assets (EBIT) 6.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −9%, 300119 screens richer than that median.
Fair Value models
Bear ¥8.46Fair Value ¥15.08Bull ¥19.12
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.3378 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.75/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
Start year 2020 (pandemic). Over 10 years: +15.7% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−0.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.0%
Dividend (yield on the price)2.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−3% vs 12%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 13%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+31.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +29.6% a year for the price and +9.3% for the forecasts.
Compare Tianjin Ringpu Bio Tech with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks
Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside−10% · Above median
Profitability
Return on equity (TTM)8% · Above median
Return on assets3% · Above median
Net margin (TTM)12% · Above median
Operating margin (TTM)15% · Above median
Growth and dividend
Revenue growth1% · Below median
Dividend yield (TTM)2.4% · Above median
Balance sheet
Debt / equity0.08× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Tianjin Ringpu Bio Tech Fair Value". https://www.fairvalue-calculator.com/stock/300119
Frequently asked questions
Is Tianjin Ringpu Bio Tech (300119) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥15.08 versus a price of ¥16.66, about −9% upside (fairly valued).
What is the fair value of 300119?
Our model-based fair value for Tianjin Ringpu Bio Tech is ¥15.08 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥16.66.
What is the quality score of 300119?
Tianjin Ringpu Bio Tech has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tianjin Ringpu Bio Tech (300119)?
Our model-based price target is the fair value of ¥15.08 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario ¥8.46, optimistic scenario ¥19.12. It is a calculation from audited fundamentals, not an analyst target.
What is the Tianjin Ringpu Bio Tech stock forecast for 2026?
Our models put fair value at ¥15.08, about −9% upside versus a price of ¥16.66 (fairly valued). Cautious scenario ¥8.46, optimistic scenario ¥19.12. The calculation is refreshed regularly with new filings.
What is the revenue of Tianjin Ringpu Bio Tech (300119)?
Tianjin Ringpu Bio Tech reported trailing-twelve-month revenue of about 3.4B CNY (latest available figure, as of Sep 24, 2026).
Does Tianjin Ringpu Bio Tech pay a dividend?
Tianjin Ringpu Bio Tech currently shows a dividend yield of about 2.40% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Tianjin Ringpu Bio Tech (300119)?
For today's price to be fair in a discounted-cash-flow model, Tianjin Ringpu Bio Tech would have to grow free cash flow by +31.8 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 300119 use?
Our models discount Tianjin Ringpu Bio Tech at 10.4 %: a base by market capitalisation (small), damped by beta 0.25, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Tianjin Ringpu Bio Tech that is +31.8 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Tianjin Ringpu Bio Tech (300119) delivered so far?
Over the past 5 years revenue at Tianjin Ringpu Bio Tech grew +11.2 % a year. The price currently implies +31.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Tianjin Ringpu Bio Tech (300119) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Tianjin Ringpu Bio Tech (+31.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Tianjin Ringpu Bio Tech (300119)?
The free-cash-flow yield on the price is 1.57 %: that much free cash flow Tianjin Ringpu Bio Tech produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Tianjin Ringpu Bio Tech (300119)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tianjin Ringpu Bio Tech it is ¥15.08 per share (as of Sep 24, 2026), against a price of ¥16.66. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Tianjin Ringpu Bio Tech stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 300119 trades above its calculated fair value: price ¥16.66, fair value ¥15.08, a gap of about −9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300119?
No. The price is what the market pays today (¥16.66); the fair value is what the company's own numbers justify (¥15.08). For Tianjin Ringpu Bio Tech the two are ¥1.58 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tianjin Ringpu Bio Tech worth?
The market values Tianjin Ringpu Bio Tech at about 7.7B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥16.66; our models calculate a fair value of ¥15.08 per share.
What do the bullish and bearish scenarios say about 300119?
Our models span a range for Tianjin Ringpu Bio Tech: cautious scenario ¥8.46, base ¥15.08, optimistic ¥19.12 per share (as of Sep 24, 2026, price ¥16.66). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300119?
Tianjin Ringpu Bio Tech trades at a price-to-earnings ratio of 19.4 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥15.08 is built from several models across several years. Other multiples: P/B 1.7, P/S 2.3, EV/EBITDA 12.4.
How solid is the balance sheet of Tianjin Ringpu Bio Tech (300119)?
Balance-sheet figures for Tianjin Ringpu Bio Tech (as of Sep 24, 2026): return on equity 8.3%, debt of 0.08 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 300119 from its 52-week high?
Tianjin Ringpu Bio Tech trades at ¥16.66, about 24% below its 52-week high of ¥22.05 and 16% above the low of ¥14.38 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of ¥15.08 is for.
Which stocks are comparable to Tianjin Ringpu Bio Tech?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tianjin Ringpu Bio Tech stock attractive at the current price?
The data as of Sep 24, 2026: price ¥16.66, calculated fair value ¥15.08 (−9%), Quality Score 57/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300119 calculated?
We run Tianjin Ringpu Bio Tech through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥15.08, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Tianjin Ringpu Bio Tech itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tianjin Ringpu Bio Tech (300119)?
The closing price on Sep 24, 2026 was ¥16.66. Our model-based fair value is ¥15.08, about −9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tianjin Ringpu Bio Tech right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (¥8.46 to ¥19.12) leaves room in how you read the outcome.
Where does the earnings growth of Tianjin Ringpu Bio Tech (300119) come from?
Earnings per share at Tianjin Ringpu Bio Tech grew +13.7 % a year from 2013 to 2024. Broken into its drivers: revenue per share +13.3 %, EBIT margin +3.0 %, tax rate +0.7 %, residual (interest, one-offs) −3.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Tianjin Ringpu Bio Tech
How large is the market capitalisation of Tianjin Ringpu Bio Tech (300119)?
The market capitalisation of Tianjin Ringpu Bio Tech is 7.7B CNY (≈ $1.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tianjin Ringpu Bio Tech (300119)?
The price-to-sales ratio of Tianjin Ringpu Bio Tech is 2.28 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tianjin Ringpu Bio Tech (300119)?
Earnings per share at Tianjin Ringpu Bio Tech are ¥0.8600 (price ÷ EPS = P/E 19.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Tianjin Ringpu Bio Tech (300119)?
The dividend yield of Tianjin Ringpu Bio Tech is 2.4% (payout 46.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tianjin Ringpu Bio Tech (300119)?
The net margin of Tianjin Ringpu Bio Tech is 11.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tianjin Ringpu Bio Tech (300119)?
The return on equity (ROE) of Tianjin Ringpu Bio Tech is 8.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tianjin Ringpu Bio Tech (300119)?
On an EBIT basis the return on assets of Tianjin Ringpu Bio Tech is 6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tianjin Ringpu Bio Tech (300119)?
The operating margin of Tianjin Ringpu Bio Tech is 15.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tianjin Ringpu Bio Tech (300119)?
Revenue at Tianjin Ringpu Bio Tech is growing +0.5% versus a year earlier (3y avg +17.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tianjin Ringpu Bio Tech (300119)?
Earnings per share at Tianjin Ringpu Bio Tech are growing −6.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Tianjin Ringpu Bio Tech (300119) carry?
The net debt of Tianjin Ringpu Bio Tech is 503M CNY (fiscal year 2025, ≈ 4.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Tianjin Ringpu Bio Tech in the live analysis
One click puts Tianjin Ringpu Bio Tech on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
